Coya Therapeutics (NASDAQ:COYA – Get Free Report) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Coya Therapeutics to similar companies based on the strength of its dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.
Valuation and Earnings
This table compares Coya Therapeutics and its peers revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Coya Therapeutics | $7.95 million | -$21.23 million | -2.91 |
| Coya Therapeutics Competitors | $691.14 million | $10.43 million | -10.01 |
Coya Therapeutics’ peers have higher revenue and earnings than Coya Therapeutics. Coya Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Analyst Ratings
This is a summary of recent recommendations for Coya Therapeutics and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Coya Therapeutics | 1 | 0 | 6 | 0 | 2.71 |
| Coya Therapeutics Competitors | 9789 | 15058 | 45311 | 1572 | 2.54 |
Coya Therapeutics currently has a consensus target price of $15.33, suggesting a potential upside of 393.03%. As a group, “Biotechnology” companies have a potential upside of 97.70%. Given Coya Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Coya Therapeutics is more favorable than its peers.
Profitability
This table compares Coya Therapeutics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Coya Therapeutics | -270.22% | -52.05% | -46.34% |
| Coya Therapeutics Competitors | -9,046.59% | -199.78% | -30.61% |
Insider and Institutional Ownership
39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 6.1% of Coya Therapeutics shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Volatility & Risk
Coya Therapeutics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Coya Therapeutics’ peers have a beta of 1.14, suggesting that their average stock price is 14% more volatile than the S&P 500.
Summary
Coya Therapeutics peers beat Coya Therapeutics on 7 of the 13 factors compared.
Coya Therapeutics Company Profile
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
